ABCC8-Related Congenital Hyperinsulinism

ABCC8-related congenital hyperinsulinism is a genetic condition where the pancreas makes too much insulin even when blood sugar is low. The extra insulin pushes sugar from the blood into body cells and causes hypoglycemia (low blood sugar). This can start soon after birth or later in infancy or childhood. Low sugar can lead to sleepiness, poor feeding, sweating, irritability, seizures, or coma if not treated quickly. The problem sits in a “gate” on the beta-cell surface called the KATP channel. The ABCC8 gene makes a key part of this gate (a protein called SUR1). Variants (mutations) in ABCC8 can stop the gate from working. When the gate stays closed, calcium flows in, and insulin keeps coming out, even when it should stop. That is why glucose drops. NCBI+2PMC+2

ABCC8-related congenital hyperinsulinism is a genetic condition where the pancreas makes too much insulin, which drives blood sugar dangerously low, especially in newborns and infants. The ABCC8 gene encodes SUR1, a core part of the β-cell KATP_{ATP}ATP​ channel that acts like an electrical “gate” for insulin release. When ABCC8 has a harmful change, the gate can’t open properly, the cell stays “on,” and insulin keeps flowing even when blood sugar is low. This can cause seizures, poor feeding, sleepiness, or coma if not treated quickly. Some children have focal disease (a small pancreatic spot causing the problem) and can be cured by removing that spot; others have diffuse disease (all β-cells affected) and need long-term medical care and sometimes surgery. Early diagnosis and stable glucose above ~70 mg/dL protect the brain. Frontiers+2PubMed+2

How common and how severe.
Congenital hyperinsulinism is rare, but it is the most common cause of persistent severe low sugar in newborns and infants. ABCC8 and its partner gene KCNJ11 account for many cases, especially the more severe, diazoxide-unresponsive forms. Some children have milder, diazoxide-responsive disease. The age at first symptoms, the level of low sugar, and the response to medicines vary widely, even in the same family. NCBI+2PMC+2

There are two main forms in the pancreas: diffuse (all beta cells are involved) and focal (a small patch makes too much insulin). Focal disease often happens when a single paternally inherited ABCC8 variant combines with a local imprinting change (loss of the maternal 11p15 region) in that patch. Focal lesions can often be removed with surgery and “cure” the hypoglycemia. Diffuse disease may need long-term medical therapy; some severe cases historically needed near-total pancreatectomy, which raises later diabetes risk. NCBI+2Journal of Nuclear Medicine+2

---

Other names

ABCC8-related congenital hyperinsulinism can appear under several names in the literature:

• Congenital hyperinsulinism (CHI)

• Familial hyperinsulinism

• Persistent hyperinsulinemic hypoglycemia of infancy (PHHI)

• Hyperinsulinemic hypoglycemia (HH)

• KATP-HI (when due to ABCC8/KCNJ11)
  These labels describe the same core problem: too much insulin causing low blood sugar in early life. NCBI+2BioMed Central+2

---

Types

By pancreatic pattern

• Focal HI. A small area of the pancreas over-secretes insulin due to a paternal ABCC8 variant plus imprinting changes. It is often diazoxide-unresponsive, and surgery guided by 18F-DOPA PET/CT can cure it. PMC+1

• Diffuse HI. All beta cells are affected. It can be autosomal recessive (two faulty ABCC8 copies) or autosomal dominant (one faulty copy). Severity varies; recessive disease is more often severe and diazoxide-unresponsive. NCBI

By inheritance

• Autosomal recessive ABCC8-HI. Usually severe, neonatal onset, frequently diazoxide-unresponsive. NCBI

• Autosomal dominant ABCC8-HI. Often milder, may present later, and can be diazoxide-responsive, but exceptions exist. NCBI

By treatment response

• Diazoxide-responsive. Often dominant variants or milder channel defects; diazoxide keeps KATP channels open and reduces insulin release. NCBI

• Diazoxide-unresponsive. More typical for recessive ABCC8/KCNJ11 variants and for focal disease; these patients need other therapies and imaging/surgical planning. PMC

---

Causes

In strict genetics, “cause” = the ABCC8 variant. But families also ask “what else makes it happen or worse?” Below are disease causes and real-life triggers that start or worsen low sugar in ABCC8-HI.

1. Pathogenic ABCC8 variants (loss-of-function). The main cause. Different changes (missense, nonsense, splice, frameshift) all can disable SUR1. MedlinePlus

2. Defective KATP channel gating. The channel cannot open; insulin release stays “on.” PMC

3. Defective trafficking of SUR1 to the cell surface. The channel never reaches the membrane, so it cannot work. PubMed

4. Autosomal recessive inheritance. Two faulty copies give severe, early disease. NCBI

5. Autosomal dominant inheritance. One faulty copy may cause milder disease or later onset; some are still severe. NCBI

6. Focal pancreatic lesion mechanism. Paternal ABCC8 variant plus local 11p15 imprinting change causes a hyperactive insulin “nodule.” PMC+1

7. Founder variants. Certain communities carry ABCC8 founder variants linked to HI. NCBI

8. De novo variants. New ABCC8 changes can arise in the child without a parental variant. NCBI

9. Somatic (mosaic) variants in pancreas. Post-zygotic ABCC8 variants can create localized disease. OUP Academic

10. Combined gene effects. ABCC8 partners with KCNJ11; many severe, diazoxide-unresponsive cases sit in these KATP genes. PMC

11. Perinatal stress and feeding gaps (trigger). Long fasting after birth can unmask or worsen hypoglycemia in affected babies. NCBI

12. Intercurrent illness (trigger). Poor intake during sickness drops glucose supply and worsens lows. NCBI

13. High energy demand (trigger). Strenuous activity or prolonged crying can lower glucose faster. NCBI

14. Medication mismatch (trigger). In true KATP-HI, diazoxide often fails (especially recessive forms), so delayed switch to other treatments can prolong hypoglycemia. PMC

15. Delayed diagnosis (trigger). Missed early signs delay treatment; ongoing lows cause more episodes. NCBI

16. Inadequate glucose monitoring (trigger). Without close sugar checks, mild symptoms are missed, and severe lows follow. Congenital Hyperinsulinism International

17. Late genetic testing (trigger). Not testing ABCC8/KCNJ11 quickly can delay the right plan (e.g., PET-CT and focal surgery). PMC

18. Feeding intolerance (trigger). Vomiting or poor feeding reduces glucose intake. NCBI

19. Prematurity or large-for-gestational-age status (risk marker). Many ABCC8/KCNJ11 HI infants are AGA/LGA; being LGA often flags risk and diazoxide unresponsiveness. PMC

20. Progression after pancreatic surgery (long-term effect). Near-total pancreatectomy stops hypoglycemia but raises later diabetes risk, affecting long-term glucose balance. NCBI

---

Symptoms

1. Jitteriness and tremors. Early sign that the brain lacks glucose. NCBI

2. Irritability or unusual crying. Babies may be hard to console during lows. NCBI

3. Poor feeding or refusal to feed. Low sugar can reduce appetite and energy to suck. NCBI

4. Sleepiness or lethargy. The brain slows down when sugar is low. NCBI

5. Sweating and pallor. The body releases stress hormones to fight the low. NCBI

6. Seizures. Dangerous sign of neuroglycopenia; urgent treatment is needed. NCBI

7. Apnea or breathing pauses (newborns). Can occur during severe lows. NCBI

8. Low body temperature. Hypoglycemia may present with hypothermia in infants. NCBI

9. Poor muscle tone (hypotonia). The baby may feel “floppy.” NCBI

10. Blue lips or spells (cyanosis) in severe events. Reflects critical episodes. NCBI

11. Fast heart rate. A common stress response. NCBI

12. Episodes during illness or long fasts. Lows are often worse then. NCBI

13. Macrosomia at birth (often). Many babies with KATP-HI are large for gestational age. NCBI

14. Developmental concerns if lows are frequent or prolonged. Repeated neuroglycopenia can harm the brain. BioMed Central

15. Later tendency toward glucose dysregulation after major surgery. Risk of diabetes grows after near-total pancreatectomy. NCBI

---

Diagnostic tests

Diagnosis is best made during an actual low or a supervised fast, with safe hospital monitoring. Doctors look for “inappropriate insulin action” when glucose is low: insulin or C-peptide detectable, suppressed ketones and free fatty acids, and a rise in sugar after glucagon. Genetic testing then confirms the cause and guides imaging and treatment.

A) Physical examination

1. General newborn/infant exam during or soon after a low.
   Doctors check alertness, tone, color, sweating, and temperature. Findings like jitteriness, hypotonia, pallor, or hypothermia support hypoglycemia. This does not prove HI, but it tells the team to draw the right labs during the event. NCBI

2. Birth size and growth review.
   Large-for-gestational-age birthweight is common in ABCC8/KCNJ11 HI. This clue plus diazoxide unresponsiveness strongly predicts KATP-HI and guides rapid gene testing and imaging plans. PMC

3. Feeding assessment.
   Poor feeding, vomiting, or long gaps between feeds can trigger lows in affected babies. Recording feeding patterns helps time critical blood tests. NCBI

4. Neurologic check.
   Doctors look for seizures, lethargy, or abnormal tone during lows. Early recognition prevents brain injury by speeding treatment. NCBI

B) Manual (bedside/provocation) tests

5. Frequent bedside glucose monitoring.
   Close, repeated glucose checks catch patterns and document true episodes. In HI, readings can drop quickly, especially when feeds are delayed. Congenital Hyperinsulinism International

6. Supervised fasting test (in hospital).
   Under strict monitoring, clinicians allow a short fast to see how glucose, ketones, and insulin behave. In HI, glucose falls while ketones and free fatty acids stay inappropriately low. This is a key pattern. NCBI

7. Glucagon stimulation test during a low.
   A small glucagon injection raises glucose by >30 mg/dL within ~40 minutes in HI. This shows the liver still has glycogen and points away from primary liver or metabolic storage problems. It is nearly pathognomonic in the right setting. NCBI

8. Calculate glucose infusion requirement.
   If a baby needs >15 mg/kg/min of IV glucose to keep sugars safe, HI is very likely. Normal needs are much lower. NCBI

C) Laboratory & pathological tests

9. Insulin level during hypoglycemia.
   In HI, insulin is inappropriately detectable when glucose is <50 mg/dL. Exact cut-offs vary by lab, so doctors also use “surrogate” markers. NCBI

10. C-peptide during hypoglycemia.
    Detectable C-peptide shows the insulin is endogenous (coming from the pancreas), not injected. NCBI

11. Beta-hydroxybutyrate and acetoacetate (ketones).
    These are low in HI, because insulin blocks fat breakdown and ketone production. Low ketones during a low is a strong HI clue. NCBI

12. Free fatty acids (FFA).
    FFAs are also suppressed during a low, reflecting insulin’s anti-lipolytic effect. NCBI

13. Counter-regulatory hormones (cortisol, growth hormone).
    These may be normal or elevated as the body fights the low; they help exclude pituitary/adrenal causes. NCBI

14. Plasma ammonia (to rule in/out specific forms).
    Ammonia is normal in ABCC8-HI but elevated in GLUD1-HI; measuring it helps sort the genetic subtype. NCBI

15. Comprehensive genetic testing (rapid ABCC8/KCNJ11 first).
    Fast testing of ABCC8/KCNJ11 is crucial in diazoxide-unresponsive HI, because finding a paternally inherited KATP variant points strongly to focal disease and the need for 18F-DOPA PET/CT and possible curative surgery. If negative, broader panels or exome/genome can follow. PMC

16. Pancreatic pathology (when surgery occurs).
    If tissue is removed, the pathologist looks for focal adenomatous hyperplasia or diffuse beta-cell involvement to confirm type and guide future care. NCBI

D) Electrodiagnostic tests

17. EEG during or after seizures.
    Seizures are a serious sign of neuroglycopenia. EEG documents seizure activity and helps guide rescue and longer-term neuroprotection steps. It does not diagnose HI but shows the brain impact of low sugar. NCBI

18. Cardiorespiratory monitoring.
    Continuous ECG and oxygen monitoring during evaluation help detect apnea, bradycardia, or stress responses that can accompany severe lows in infants. NCBI

E) Imaging tests

19. 18F-DOPA PET/CT (or PET/MRI) for focal vs diffuse.
    This scan is the method of choice to locate focal lesions in KATP-HI. If a paternally inherited ABCC8 variant is found, PET/CT is especially helpful, and resection of the focus can be curative. Journal of Nuclear Medicine+1

20. Targeted pancreatic MRI/CT (when PET is unavailable).
    MRI/CT are less sensitive than 18F-DOPA PET for focal HI but may still help surgical planning in centers without PET access. Imaging choice depends on local expertise and logistics. BioMed Central

Non-pharmacological treatments (therapies & other measures)

Each item includes a short description (~150 words), purpose, and mechanism.

1. Rapid oral glucose at first signs of low sugar
   What it is: For mild symptoms (jitteriness, sweating, pallor), give fast sugar (breast milk, formula, or oral glucose gel per local protocol).
   Purpose: Lift blood glucose quickly to protect the brain.
   Mechanism: Glucose enters the bloodstream rapidly to counter insulin’s action. (This is supportive—it does not fix the ABCC8 channel, but it buys safety.) BioMed Central

2. IV dextrose infusion in hospital
   What it is: Continuous IV 10–20% dextrose adjusted to keep glucose ≥70 mg/dL, often started in NICU/ED.
   Purpose: Immediate stabilization and prevention of neuroglycopenia.
   Mechanism: Direct glucose delivery bypasses the gut and instantly raises plasma glucose against excess insulin. BioMed Central

3. Emergency glucagon administration (caregiver-taught)
   What it is: Caregivers learn to give glucagon if severe hypoglycemia or when the child won’t take sugar by mouth.
   Purpose: Life-saving bridge until medical help or IV glucose.
   Mechanism: Glucagon releases liver glycogen to raise blood glucose. (Note: requires adequate glycogen stores.) FDA Access Data+1

4. Frequent small feeds (breast milk/formula) and scheduled night feeds
   What it is: Structured feeding plan with shorter gaps, sometimes with a nasogastric (NG) or gastrostomy tube if needed.
   Purpose: Prevent long fasts that trigger hypoglycemia.
   Mechanism: Keeps a steady flow of glucose from food to offset inappropriate insulin secretion. BioMed Central

5. Continuous enteral feeding (pump feeds) in difficult cases
   What it is: Overnight continuous feeds by NG/G-tube when frequent bolus feeds aren’t enough.
   Purpose: Protects through the longest “fast” (night).
   Mechanism: Provides a constant stream of carbohydrate; blunts dips from persistent insulin. BioMed Central

6. Dietitian-led carbohydrate planning
   What it is: Pediatric dietitian optimizes daytime carbs/protein/fat and sets safe fasting limits; educates family on rescue carbs.
   Purpose: Individualize intake to growth and glucose targets.
   Mechanism: Aligns meal timing and composition with glucose needs in HI. Frontiers

7. Avoidance of prolonged fasting & sick-day rules
   What it is: Clear plan to shorten fasting during illness; earlier feeds, lower fasting targets, and earlier hospital review.
   Purpose: Reduce risk of hypoglycemia during stress or anorexia.
   Mechanism: Illness hormones plus persistent insulin raise risk; proactive carbs counter this. ispad.org

8. Home glucose monitoring (fingerstick or CGM when appropriate)
   What it is: Regular checks (and alarms with CGM) to spot lows early.
   Purpose: Early detection, quicker rescue.
   Mechanism: Data-driven response prevents neuroglycopenia. (Use under endocrine guidance.) Wiley Online Library

9. Fever/illness hydration and carbohydrate support
   What it is: Oral rehydration with added carbs (e.g., oral glucose solutions) per care plan; lower threshold for ED if poor intake.
   Purpose: Prevent dehydration and low glucose.
   Mechanism: Maintains substrate flow in the face of persistent insulin. BioMed Central

10. Education on hypoglycemia signs & rescue
    What it is: Teach caregivers to recognize subtle symptoms (irritability, pallor, tremor) and to act.
    Purpose: Speed to treatment saves brain function.
    Mechanism: Faster recognition → faster glucose correction. BioMed Central

11. 18^{18}18F-DOPA PET/CT for focal vs diffuse disease
    What it is: Imaging before surgery to locate a focal hotspot.
    Purpose: Enables targeted lesionectomy and potential cure.
    Mechanism: DOPA uptake marks hyper-active islet tissue. PMC+1

12. Multidisciplinary HI center care
    What it is: Coordinated team (endocrinology, radiology, surgery, dietetics).
    Purpose: Faster diagnosis, tailored therapy, safer outcomes.
    Mechanism: Expertise with high case volumes improves selection of medicine vs surgery and reduces complications. Children’s Hospital of Philadelphia

13. Developmental follow-up & early intervention services
    What it is: Neurodevelopmental screening and therapy if needed.
    Purpose: Catch and treat learning or motor delays early.
    Mechanism: Preventable brain injury from hypoglycemia warrants structured surveillance. BioMed Central

14. Preoperative fasting minimization protocols
    What it is: Special surgical fasting plans (IV dextrose, dextrose-containing clear fluids until closer to anesthesia).
    Purpose: Prevent peri-operative hypoglycemia.
    Mechanism: Maintains glucose delivery when NPO. ispad.org

15. Safe school/day-care plan
    What it is: Written plan for feeds, checks, rescue sugar, and when to call parents/EMS.
    Purpose: Keep child safe outside home.
    Mechanism: Extends consistent hypoglycemia prevention to school settings. Wiley Online Library

16. Genetic counseling for family planning
    What it is: Counseling about recurrence risk, carrier testing, and prenatal options.
    Purpose: Informed decisions for future pregnancies.
    Mechanism: ABCC8 variants can be recessive or dominant; counseling clarifies risks. MedlinePlus

17. Medical alert identification
    What it is: Bracelet/card stating “Congenital Hyperinsulinism—risk of severe hypoglycemia.”
    Purpose: Faster, appropriate care in emergencies.
    Mechanism: Guides responders to check glucose and give dextrose/glucagon promptly. BioMed Central

18. Sleep safety & night monitoring plan
    What it is: More frequent checks overnight during illness or dose changes.
    Purpose: Prevent unrecognized nocturnal hypoglycemia.
    Mechanism: Higher vigilance during the longest fast. Wiley Online Library

19. Vaccination as per schedule
    What it is: Routine immunizations; prevent systemic illness that can destabilize glucose.
    Purpose: Reduce hypoglycemia-triggering infections.
    Mechanism: Fewer febrile illnesses → fewer sick-day hypoglycemia events. Wiley Online Library

20. Transition planning to adolescence/adulthood
    What it is: Structured handover of care, self-management skills, and understanding of long-term risks (including post-pancreatectomy diabetes).
    Purpose: Maintain safety and autonomy.
    Mechanism: Sustained monitoring and education reduce acute events and long-term complications. Children’s Hospital of Philadelphia

---

Drug treatments

For each medicine: ~150 words with class, usual dosing/time (from label when applicable; HI dosing is specialist-directed), purpose, mechanism, notable side effects. Indications on FDA labels are often not HI—we cite labels for pharmacology/safety; clinicians adapt them off-label for HI where supported by evidence.

1) Diazoxide (PROGLYCEM®) – first-line in many forms, but often ineffective in KATP_{ATP}ATP​ channel mutations like ABCC8 diffuse disease
Class: Potassium-channel opener.
Dose/Time (label): Oral suspension/capsules; pediatric dosing individualized; label indicates pediatric hypoglycemia due to hyperinsulinism; dosing divided 2–3×/day.
Purpose in HI: Try to open KATP_{ATP}ATP​ channels to turn insulin “off.”
Mechanism: Activates SUR1-KATP_{ATP}ATP​ channel → β-cell hyperpolarization → less insulin release.
Side effects: Fluid retention/edema, hypertrichosis, nausea; monitor sodium/water and heart status; can cause pulmonary hypertension in infants (specialist monitoring). Note: Ineffective in many ABCC8/KCNJ11 loss-of-function cases because the channel cannot respond. FDA Access Data+2BioMed Central+2

2) Octreotide (SANDOSTATIN®) – widely used off-label when diazoxide fails
Class: Somatostatin analogue.
Dose/Time (label for other indications): SC/IV multiple daily doses; dose titration based on response. Long-acting (see drug #5).
Purpose in HI: Suppress insulin secretion acutely and between feeds.
Mechanism: Activates somatostatin receptors on β-cells → inhibits Ca2+^{2+}2+-dependent insulin exocytosis.
Side effects: GI upset, gallstones/biliary sludge with long-term use, bradycardia, QT effects; growth concerns—monitor carefully in children. FDA Access Data+2FDA Access Data+2

3) Lanreotide (SOMATULINE® DEPOT) – long-acting somatostatin analogue, off-label for HI maintenance
Class: Somatostatin analogue.
Dose/Time (label for approved indications): 120 mg deep SC every 4 weeks (for NETs/acromegaly on label).
Purpose in HI: Longer coverage to reduce insulin between feeds/overnight.
Mechanism: Somatostatin-receptor activation reduces insulin secretion.
Side effects: Injection-site pain, GI effects, gallstones; periodic monitoring recommended. FDA Access Data+1

4) Glucagon for injection (multiple brands) – rescue for severe hypoglycemia
Class: Hyperglycemic hormone.
Dose/Time (label): SC/IM/IV per weight; onset minutes; caregivers trained to mix and inject.
Purpose in HI: Emergency raise of glucose when child cannot take carbs orally.
Mechanism: Mobilizes liver glycogen to glucose.
Side effects: Nausea/vomiting; may be less effective if glycogen depleted; repeat dosing and IV dextrose may be required. FDA Access Data+1

5) Octreotide LAR (SANDOSTATIN® LAR Depot) – monthly form to simplify regimens; off-label in HI
Class: Long-acting somatostatin analogue.
Dose/Time (label for other indications): IM every 4 weeks with dose titration.
Purpose/Mechanism: Same as #2, but sustained.
Side effects: Similar to octreotide immediate-release; monitor for gallstones, GI effects, and growth. FDA Access Data

6) Pasireotide (SIGNIFOR®) – case-report/series use in severe diazoxide-resistant ABCC8-HI
Class: Broad somatostatin analogue (high SSTR5 affinity).
Dose/Time (label for Cushing disease/acromegaly): SC or LAR regimens titrated to effect.
Purpose in HI: Alternative when octreotide/lanreotide fail.
Mechanism: Stronger suppression of insulin via SSTR5-rich β-cells.
Side effects: Hyperglycemia (paradoxically), GI upset, gallstones, bradycardia; specialist-only use. Frontiers

7) Sirolimus (RAPAMUNE®) – select refractory cases, specialist centers only (off-label)
Class: mTOR inhibitor/immunosuppressant.
Dose/Time (label): Oral; levels monitored; black-box warnings; infection risk.
Purpose in HI: Reduce β-cell activity/insulin secretion in severe diffuse disease not amenable to surgery.
Mechanism: mTOR pathway modulation reduces insulin release and β-cell hyperfunction.
Side effects: Immunosuppression, mouth ulcers, hyperlipidemia, edema; requires careful risk-benefit assessment. FDA Access Data+1

8) Everolimus (AFINITOR®) – mechanistic cousin of sirolimus; highly selected off-label use
Class: mTOR inhibitor.
Dose/Time (label): Oral once daily; therapeutic drug monitoring; infection and metabolic risks.
Purpose/Mechanism in HI: Same pathway rationale as sirolimus in refractory diffuse HI.
Side effects: Mucositis, infections, hyperlipidemia, cytopenias—specialist monitoring needed. (FDA label available for oncology indications; off-label safety principles apply.) FDA Access Data

9) Nifedipine (PROCARDIA/ADALAT) – calcium-channel blocker; limited/variable benefit
Class: Dihydropyridine calcium-channel blocker.
Dose/Time (label for hypertension/angina): ER tablets once daily or capsules; pediatric HI dosing is off-label and uncommon.
Purpose in HI: Theoretical reduction of Ca2+^{2+}2+-dependent insulin exocytosis; clinical results mixed; not first-line.
Side effects: Hypotension, flushing, edema; careful selection needed. FDA Access Data+2FDA Access Data+2

10) Dextrose injection (IV dextrose 10–20%) – core acute therapy in hospital
Class: Carbohydrate solution.
Dose/Time (label): Continuous IV infusion with rate adjusted by glucose checks.
Purpose: Immediate correction of neuroglycopenia.
Mechanism: Direct plasma glucose supply overrides insulin’s effect. (Multiple USP labels exist; institutional protocols guide concentration/rate.) BioMed Central

11) Dasiglucagon (ZEGALOGUE®) – ready-to-use glucagon analogue; rescue
Class: Glucagon analogue.
Dose/Time (label): Pre-filled autoinjector/ syringe; rapid effect.
Purpose/Mechanism: Same as glucagon; user-friendly device for caregivers.
Side effects: Nausea, injection-site reactions. (FDA label supports severe hypoglycemia treatment; HI use is extrapolated rescue.) FDA Access Data

12) Glucagon nasal (BAQSIMI®) – needle-free rescue option
Class: Intranasal glucagon powder.
Dose/Time (label): Single-use intranasal device; rapid effect.
Purpose/Mechanism: Liver glycogenolysis despite ongoing insulin; easy caregiver use.
Side effects: Nasal irritation, nausea. (Rescue use; label for severe hypoglycemia.) FDA Access Data

13) Hydrochlorothiazide (adjunct to diazoxide-related edema)
Class: Thiazide diuretic.
Dose/Time (label for hypertension/edema): Oral once or twice daily; pediatric dosing per clinician.
Purpose in HI: Manage fluid retention from diazoxide so the child can stay on a helpful dose.
Mechanism: Natriuresis reduces edema/CHF risk.
Side effects: Hypokalemia, photosensitivity; monitor electrolytes. (Adjunctive, not a treatment for HI itself.) FDA Access Data

14) Furosemide (alternative diuretic for diazoxide edema)
Class: Loop diuretic.
Dose/Time (label): Oral/IV; individualized dosing.
Purpose: Control significant fluid overload if thiazide is unsuitable.
Mechanism: Loop natriuresis; reduces edema.
Side effects: Electrolyte loss, ototoxicity at high IV doses. (Adjunctive only.) FDA Access Data

15) Somatostatin (native hormone, hospital IV)
Class: Endogenous peptide; short half-life.
Dose/Time: Continuous IV infusion in ICU as a trial when analogues unavailable.
Purpose/Mechanism: Direct insulin suppression via somatostatin receptors.
Side effects: Bradycardia, GI effects; typically a bridge. (Pharmacology parallels octreotide; institutional use varies.) FDA Access Data

16) Nutritional glucose polymers (e.g., maltodextrin add-ins)
Class: Medical-nutrition carbohydrate.
Dose/Time: Added to feeds under dietitian guidance.
Purpose: Increase carbohydrate density without excessive volume.
Mechanism: Sustained glucose delivery against persistent insulin. (Clinical nutrition practice resource.) Frontiers

17) Parenteral nutrition with dextrose (when enteral feeding not possible)
Class: IV nutrition solution.
Dose/Time: PICC-line; tailored by weight and labs.
Purpose: Maintain glucose and growth when gut rest or surgery requires NPO.
Mechanism: Continuous systemic substrate provision. BioMed Central

18) Long-acting lanreotide/octreotide rotation strategies
Class: Somatostatin analogue scheduling approach.
Dose/Time: Monthly depot with or without short-acting overlap.
Purpose: Smoother control, fewer injections.
Mechanism: Sustained receptor activation to limit insulin bursts.
Side effects: As above; gallstone risk. FDA Access Data

19) Specialty center protocols combining dextrose + analogue + rescue glucagon
Class: Programmatic regimen.
Dose/Time: Center-specific.
Purpose: Keep glucose safe pending genetics/imaging and surgical decision.
Mechanism: Layered physiological countermeasures. Children’s Hospital of Philadelphia

20) (Important reality check) There are not 20 distinct, well-validated anti-hypoglycemia drugs specifically for ABCC8-HI. The list above combines the core medications, their long-acting counterparts, rescue options, and supportive pharmacotherapy used by HI teams. Treatment is individualized, and many agents are off-label and require expert supervision. BioMed Central

Dietary molecular supplement items

1. Fast-acting oral glucose (medical-grade gels/solutions) – Dose: per label/weight. Function/Mechanism: Rapid glucose to reverse mild hypoglycemia. (Rescue—do not replace feeds/meds.) BioMed Central

2. Maltodextrin powders (feed fortification) – Dose: dietitian-set grams per feed. Function: Increases carbohydrate density to prevent dips. Mechanism: Steadier glucose delivery. Frontiers

3. Polymeric formulas with higher carb content – Dose: per diet plan. Function: Practical way to meet carb targets if intake is low. Mechanism: Calorie-dense carbs offset insulin. Frontiers

4. Electrolyte-carb oral solutions for sick days – Dose: per plan. Function: Hydration + carbs when ill. Mechanism: Maintains glucose access during stress. BioMed Central

5. Medium-chain triglyceride add-ins (selected cases) – Dose: clinician/dietitian guided. Function: Extra calories; does not raise glucose rapidly. Mechanism: Fat calories to support growth; not a hypoglycemia rescue. Frontiers

6. Protein-balanced feeds – Dose: age-appropriate grams/day. Function: Satiation and steady nutrient delivery. Mechanism: Protein delays gastric emptying; complements carb plan. Frontiers

7. Vitamin D & standard micronutrient adequacy – Dose: per pediatric guidelines. Function: General health; no direct HI effect. Mechanism: Corrects deficiency risk in medically complex infants. Wiley Online Library

8. Iron per screen if deficient – Dose: per labs. Function: Treat anemia affecting growth/energy; no direct HI fix. Mechanism: Restores hematologic health in high-needs infants. Wiley Online Library

9. Avoid unproven “insulin-lowering” supplements – Dose: n/a. Function: Safety warning. Mechanism: Many products lack data and may be unsafe in infants. Stick to clinician-approved nutrition only. Wiley Online Library

10. Caregiver training on measuring and mixing supplements – Dose: education. Function: Prevent dosing errors and accidental underfeeding. Mechanism: Accuracy supports glucose stability. Frontiers

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity boosters,” regenerative medicines, or stem-cell drugs for ABCC8-related HI. Using immunosuppressants like sirolimus/everolimus is a risk-managed, off-label strategy in highly selected refractory cases—not a regenerative cure—and comes with serious adverse effects and black-box warnings. Families should avoid clinics advertising “stem-cell cures” for HI. If a center proposes sirolimus/everolimus, they should explain goals, alternatives, and monitoring in detail. FDA Access Data+1

---

Surgeries (what is done and why)

1. Focal lesionectomy (curative when focal disease)
   Procedure: Use 18^{18}18F-DOPA PET/CT to locate the focal spot; surgeon removes only that area.
   Why: Eliminates the insulin-overproducing focus and preserves normal pancreas; ~97% cure in expert centers. Children’s Hospital of Philadelphia+1

2. Near-total pancreatectomy (diffuse disease, diazoxide-unresponsive)
   Procedure: Remove ~95–98% of the pancreas in specialized centers.
   Why: Palliative reduction of insulin output when medicine fails; reduces severe hypoglycemia but does not cure diffuse HI; risk of insulin-dependent diabetes later. PMC+2PubMed+2

3. Partial pancreatectomy tailored by intra-op pathology
   Procedure: Multiple biopsies to confirm focal vs diffuse; resection extent tailored.
   Why: Balance hypoglycemia control with preservation of endocrine/exocrine function. Children’s Hospital of Philadelphia

4. Gastrostomy tube placement
   Procedure: Place a feeding tube during surgery when prolonged enteral support is expected.
   Why: Enables safe overnight feeds and medication delivery to prevent lows. Children’s Hospital of Philadelphia

5. Repeat lesion exploration (rare)
   Procedure: Re-image and re-operate if persistent focal disease suspected.
   Why: Achieve cure when initial focus was missed or multifocality suspected. PMC

---

Preventions

1. Early genetic testing and HI-center referral (faster right-treatment). PMC

2. Written feeding/monitoring plan to avoid prolonged fasting. BioMed Central

3. Teach caregivers rescue steps and keep glucagon on hand. FDA Access Data

4. Night/illness monitoring with lower thresholds for action. Wiley Online Library

5. Use 18^{18}18F-DOPA PET/CT before any surgery to define focal vs diffuse. PMC

6. Regular growth and development follow-up after stabilization. BioMed Central

7. Manage diazoxide side effects proactively (edema → consider diuretics if appropriate). FDA Access Data

8. Vaccinations on schedule to reduce illness-triggered hypoglycemia. Wiley Online Library

9. Medical alert ID for emergencies. BioMed Central

10. Genetic counseling for future pregnancies and family planning. MedlinePlus

---

When to see doctors urgently

Seek immediate medical care if your child is hard to wake, seizing, vomiting repeatedly, refusing feeds, or has glucose readings below your team’s safety threshold (often <70 mg/dL) that do not respond to oral glucose or glucagon, or if there’s breathing trouble or cyanosis. Go to the ED for any recurrent lows, especially during illness, or if you’re using higher and higher dextrose/feeds to maintain safe sugars. After surgery, call if there’s fever, wound redness, uncontrolled pain, or frequent highs/lows suggesting dosing issues. Early action prevents brain injury. BioMed Central

---

What to eat / what to avoid

Eat/Do:
• Frequent, scheduled feeds with adequate carbohydrates (dietitian-planned). Frontiers
• Use fast carbs at first signs of lows (per plan). BioMed Central
• Consider carb fortification (maltodextrin) if volumes are limited—only under dietitian guidance. Frontiers
• Maintain hydration, especially during fever/illness. BioMed Central
• Ensure micronutrient adequacy (vitamin D, iron if deficient). Wiley Online Library

Avoid/Caution:
• Prolonged fasting—plan overnight feeds if directed. BioMed Central
• Unproven supplements claiming to “fix insulin” or “regenerate pancreas.” FDA Access Data
• Skipping caregiver training on rescue and mixing fortified feeds. Frontiers
• Ignoring side-effect monitoring on diazoxide or analogues (edema, gallstones). FDA Access Data+1
• Delaying re-evaluation during growth spurts or illnesses. Wiley Online Library

---

FAQs

1) Is ABCC8-HI curable?
Focal disease can be cured by removing the focal lesion. Diffuse disease is not cured by surgery but may become safer with medical therapy or near-total pancreatectomy; long-term diabetes risk rises after large resections. Children’s Hospital of Philadelphia+1

2) Why doesn’t diazoxide always work in ABCC8-HI?
Diazoxide needs a working SUR1-KATP_{ATP}ATP​ channel. In many ABCC8 loss-of-function variants, the channel can’t open, so diazoxide doesn’t help. BioMed Central

3) How does octreotide help?
It mimics somatostatin and blocks insulin release, often used when diazoxide fails; long-acting forms reduce injection frequency but need monitoring for gallstones and growth. FDA Access Data

4) Is 18^{18}18F-DOPA PET/CT really necessary?
It is the key test to distinguish focal vs diffuse HI and plan curative surgery if focal. It’s more informative than older invasive tests in most centers. PMC+1

5) What are the biggest dangers of untreated HI?
Repeated neuroglycopenia can cause seizures and developmental delay. Keeping glucose safe from day one is the main goal. BioMed Central

6) Will my child outgrow HI?
Some milder forms improve; others require longer-term care. Genetics and response to therapy guide outlook. PMC

7) What are the long-term risks after pancreatectomy?
Mainly diabetes later in childhood/adolescence and possible exocrine insufficiency; ongoing follow-up is needed. Children’s Hospital of Philadelphia

8) Are mTOR inhibitors safe?
They can help in select refractory cases but carry immunosuppression risks and need tight specialist monitoring. FDA Access Data

9) Do calcium-channel blockers work?
Evidence is mixed/limited; they’re not first-line and are usually tried only in special situations. BioMed Central

10) Can diet alone manage ABCC8-HI?
Diet helps prevent lows but does not fix the insulin oversecretion. Most children need medical therapy and sometimes surgery. BioMed Central

11) Are there stem-cell cures?
No approved stem-cell or regenerative cures for ABCC8-HI exist. Be cautious of unregulated offerings. FDA Access Data

12) Why is glucagon not always effective?
It needs liver glycogen to work; during prolonged fasting or illness, glycogen may be low. IV dextrose may be necessary. FDA Access Data

13) What is the goal glucose?
Teams generally aim to maintain glucose ≥70 mg/dL, especially in infants at neurodevelopmental risk. Plans are individualized. Children’s Hospital of Philadelphia

14) Who should manage my child?
A specialized HI center with endocrinology, imaging, and surgery expertise improves outcomes, especially for surgical decision-making. Children’s Hospital of Philadelphia

15) Will my child have normal development?
With early stabilization and careful follow-up, many children do well. Developmental monitoring ensures early support if needed. BioMed Central

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.